A population-based comparison of European and North American sinonasal cancer survival

EUROCARE-5 Working Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS.

Original languageEnglish (US)
Pages (from-to)815-824
Number of pages10
JournalAuris Nasus Larynx
Volume45
Issue number4
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Survival
Population
Neoplasms
Registries
Epidemiology
Databases
Eastern Europe
Geographic Locations
National Cancer Institute (U.S.)
Age Groups

Keywords

  • Europe
  • International
  • Population-based
  • Relative survival
  • SEER
  • Sinonasal cancer
  • Surveillance Epidemiology End Results
  • Survival
  • United States

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

A population-based comparison of European and North American sinonasal cancer survival. / EUROCARE-5 Working Group.

In: Auris Nasus Larynx, Vol. 45, No. 4, 01.08.2018, p. 815-824.

Research output: Contribution to journalArticle

EUROCARE-5 Working Group. / A population-based comparison of European and North American sinonasal cancer survival. In: Auris Nasus Larynx. 2018 ; Vol. 45, No. 4. pp. 815-824.
@article{6de18640018a46b38155ce2e13ff05a7,
title = "A population-based comparison of European and North American sinonasal cancer survival",
abstract = "Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3{\%}) and the US (58.3{\%}). Most patients were over 55 years in Europe (77.0{\%}) and the US (69.5{\%}). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2{\%}; 95{\%} CI = [43.9, 52.4]) and Europe (38.5{\%}; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8{\%}; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1{\%}; [34.0, 40.6]). The aggregate European 5-year RS was 48.1{\%} [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS.",
keywords = "Europe, International, Population-based, Relative survival, SEER, Sinonasal cancer, Surveillance Epidemiology End Results, Survival, United States",
author = "{EUROCARE-5 Working Group} and Unsal, {Aykut A} and Suat Kılı{\cc} and Dubal, {Pariket M.} and Soly Baredes and Eloy, {Jean Anderson}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.anl.2017.09.009",
language = "English (US)",
volume = "45",
pages = "815--824",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - A population-based comparison of European and North American sinonasal cancer survival

AU - EUROCARE-5 Working Group

AU - Unsal, Aykut A

AU - Kılıç, Suat

AU - Dubal, Pariket M.

AU - Baredes, Soly

AU - Eloy, Jean Anderson

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS.

AB - Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS.

KW - Europe

KW - International

KW - Population-based

KW - Relative survival

KW - SEER

KW - Sinonasal cancer

KW - Surveillance Epidemiology End Results

KW - Survival

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85031748803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031748803&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2017.09.009

DO - 10.1016/j.anl.2017.09.009

M3 - Article

C2 - 29056464

AN - SCOPUS:85031748803

VL - 45

SP - 815

EP - 824

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 4

ER -